On April 10th, Wuxi Biologics announced that it will spend 199 million Hong Kong dollars to repurchase 10.08 million shares.

WUXI BIO (02269) announced that on April 10, 2025, the company spent 199 million Hong Kong dollars to repurchase 10.08 million shares at a repurchase price of 19.32-20.4 Hong Kong dollars per share. On the same day, in accordance with the company's first pre-emptive rights plan adopted on January 5, 2016 (revised on August 10, 2016), ordinary shares of 10,000 were issued for exercising options.